Oppenheimer & Co. Inc. acquired a new position in Grail, Inc. (NASDAQ:GRAL – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 10,669 shares of the company’s stock, valued at approximately $190,000.
A number of other hedge funds have also recently made changes to their positions in GRAL. FNY Investment Advisers LLC bought a new stake in shares of Grail in the 4th quarter worth approximately $26,000. New York State Common Retirement Fund bought a new stake in Grail during the 4th quarter valued at $59,000. Wilmington Savings Fund Society FSB bought a new stake in Grail during the 4th quarter valued at $64,000. Manchester Capital Management LLC bought a new stake in Grail during the 4th quarter valued at $123,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Grail during the 4th quarter valued at $127,000.
Grail Price Performance
Shares of Grail stock opened at $32.88 on Monday. The company’s fifty day simple moving average is $30.64 and its two-hundred day simple moving average is $20.87. Grail, Inc. has a 12-month low of $12.33 and a 12-month high of $63.99.
Wall Street Analyst Weigh In
A number of research firms recently commented on GRAL. Wolfe Research began coverage on shares of Grail in a report on Friday, November 15th. They set a “peer perform” rating for the company. Morgan Stanley began coverage on shares of Grail in a report on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 price target for the company.
Get Our Latest Stock Analysis on Grail
Grail Company Profile
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Featured Stories
- Five stocks we like better than Grail
- What is MarketRank™? How to Use it
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- How to Invest in Biotech Stocks
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Want to see what other hedge funds are holding GRAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grail, Inc. (NASDAQ:GRAL – Free Report).
Receive News & Ratings for Grail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grail and related companies with MarketBeat.com's FREE daily email newsletter.